Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79910 | 1.00 | SYK (0.44) | SYKKLK5ITGB3ITGA2BCTSL | |
| SCHEMBL3213032 | 1.00 | SYK (0.44) | SYKKLK5ITGB3ITGA2BCTSL | |
| SCHEMBL17261863 | 0.93 | REN (0.43) | SYKKLK5CTSK | |
| SCHEMBL10073352 | 0.92 | CTSD (0.44) | KLK5 | |
| SCHEMBL4434235 | 0.92 | CTSD (0.44) | KLK5 | |
| SCHEMBL625910 | 0.92 | CTSD (0.44) | KLK5 | |
| SCHEMBL20980796 | 0.88 | CTSK (0.42) | CTSLTRPM8CTSKCTSSCTSB | |
| SCHEMBL6612201 | 0.87 | SYK (0.49) | SYKKLK5ITGB3ITGA2BCTSL | |
| SCHEMBL5795425 | 0.87 | CASP1 (0.43) | TRPM8 | |
| SCHEMBL26623362 | 0.87 | CASP1 (0.43) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8071618-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-06 | — | — | US | disclosed |
| US-7923433-B2 | Activity-based probes and methods of their preparation and use | ACTIVX BIOSCIENCES, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100041661-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2010-02-18 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-7612091-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-7553852-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1583726-A4 | ACTIVITY-BASED PROBES, AND METHODS OF THEIR PREPARATION AND USE | ACTIVX BIOSCIENCES INC (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1583726-A2 | ACTIVITY-BASED PROBES, AND METHODS OF THEIR PREPARATION AND USE | Activx Biosciences, Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1581501-A1 | 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1539701-A1 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-30 | — | — | US | disclosed |
| WO-2004058718-A1 | 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004033397-A2 | ACTIVITY-BASED PROBES, AND METHODS OF THEIR PREPARATION AND USE | ACTIVX BIOSCIENCES, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040072850-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-04-15 | — | — | US | disclosed |
| WO-2004002961-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, CASP5 | SYK 3348/4885KLK5 3268/4885ITGB3 2364/4885 |
| US-20040072850-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP2 | SYK 1837/4885KLK5 1027/4885ITGB3 4347/4885 |
| US-20100041661-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | CASP1, CASP2, CASP5 | SYK 2262/4885KLK5 510/4885ITGB3 3280/4885 |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | SYK 2961/4885KLK5 3579/4885ITGB3 2702/4885 |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | SYK 1687/4885KLK5 792/4885ITGB3 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.